Аннотация:Due to oxidative instability, arylboronic acids are not compatible with solid phase synthesis of nucleic acids. We solved this problem and, based on these findings, developed siRNA prodrugs, activated in the presence of reactive oxygen species (ROS) in vivo. These prodrugs can be used for specific targeting ROS-rich cancer cells.